IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Meridian Bioscience, Inc. (“Meridian” or the “Company”) (Nasdaq: VIVO) concerning possible violations of federal securities laws.
If you purchased shares of Meridian and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
The investigation concerns whether Meridian and certain of its officers and/or directors violated federal securities laws. On May 17, 2017, the FDA warned Meridian that lead tests conducted by the Company’s subsidiary, Magellan Diagnostics, may be incorrect. According to the FDA, tests performed on blood drawn from a vein has led to “results that are lower than the actual level of lead in the blood.” The FDA recommended discontinuation of Magellan when testing with venous blood samples. When this information was released, Meridian shares fell in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.